nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

03.10.2020 | COVID-19 | Retinal Disorders Zur Zeit gratis

Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic

verfasst von: Enrico Borrelli, Domenico Grosso, Giovanna Vella, Riccardo Sacconi, Marco Battista, Lea Querques, Ilaria Zucchiatti, Francesco Prascina, Francesco Bandello, Giuseppe Querques

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To estimate the impact of delayed care during the coronavirus disease 2019 (COVID-19) pandemic on the outcomes of patients with neovascular age-related macular degeneration (AMD).

Methods

Consecutive patients with diagnosis of neovascular AMD were consecutively enrolled between March 9, 2020, and June 12, 2020, (during and immediately after the Italian COVID-19 quarantine). During the inclusion (or pandemic) visit (V₀), patients received a complete ophthalmologic evaluation, including optical coherence tomography (OCT). Best-corrected visual acuity (BCVA) and OCT findings from the two preceding visits (V₋₁ and V₋₂) were compared with data at V₀.

Results

One-hundred patients (112 eyes) were enrolled in this study. The time interval between following visits was 110.7 ± 37.5 days within V₀ and V₋₁ and 80.8 ± 39.7 days within V₋₁ and V₋₂, respectively (P < 0.0001). BCVA was statistically worse at the V₀ visit as compared with the immediately preceding (V₋₁) visit (0.50 ± 0.43 LogMAR and 0.45 ± 0.38 LogMAR at the V₀ and V₋₁ visits, respectively; P = 0.046). On structural OCT, 91 out of 112 (81.2%) neovascular AMD eyes displayed the evidence of exudative disease activity at the V₀ visit, while 77 (68.7%) eyes exhibited signs of exudation at the V₋₁ visit (P = 0.022). No differences in terms of BCVA and OCT findings were detected between the V₋₁ and V₋₂ visits. In multiple regression analysis, the difference in BCVA between V₀ and V₋₁ visits was significantly associated with the interval time within these two visits (P = 0.026).

Conclusion

The COVID-19 pandemic-related postponement in patient care proved to be significantly associated with worse short-term outcomes in these patients.

Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606–2617. https://doi.org/10.1056/NEJMra0801537CrossRefPubMed

Spaide RF, Jaffe GJ, Sarraf D, et al (2019) Consensus nomenclature for reporting neovascular age-related macular degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group. Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.11.004

Borrelli E, Sarraf D, Freund KB, Sadda SR (2018) OCT angiography and evaluation of the choroid and choroidal vascular disorders. Prog Retin Eye Res. https://doi.org/10.1016/j.preteyeres.2018.07.002

Querques L, Parravano M, Borrelli E et al (2020) Anatomical and functional changes in neovascular AMD in remission: comparison of fibrocellular and fibrovascular phenotypes. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2018-313685

Martin DF (2018) Evolution of Intravitreal therapy for retinal diseases—from CMV to CNV: the LXXIV Edward Jackson memorial lecture. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2017.12.019

Keane PA, Sadda SR (2012) Development of anti-VEGF therapies for intraocular use: a guide for clinicians. J Ophthalmol. https://doi.org/10.1155/2012/483034

Solomon SD, Lindsley K, Vedula SS et al (2014) Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005139.pub3

Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. https://doi.org/10.1056/NEJMoa062655

Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. https://doi.org/10.1056/NEJMoa054481

10.

Regillo CD, Brown DM, Abraham P et al (2008) Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2007.10.004

11.

Sarwar S, Clearfield E, Soliman MK et al (2016) Aflibercept for neovascular age-related macular degeneration. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD011346.pub2

12.

Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. https://doi.org/10.1016/j.ophtha.2012.09.006

13.

Wecker T, Grundel B, Reichl S et al (2019) Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment. Sci Rep. https://doi.org/10.1038/s41598-019-38934-8

14.

Freund KB, Korobelnik J-F, Devenyi R, et al (2015) TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A Literature Review and Consensus Recommendations. Retina. https://doi.org/10.1097/IAE.0000000000000627

15.

Gupta OP, Shienbaum G, Patel AH et al (2010) A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration: clinical and economic impact. Ophthalmology. https://doi.org/10.1016/j.ophtha.2010.02.032

16.

Shienbaum G, Gupta OP, Fecarotta C et al (2012) Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. Am J Ophthalmol. https://doi.org/10.1016/j.ajo.2011.08.011

17.

Silva R, Berta A, Larsen M, et al (2018) Treat-and-extend versus monthly regimen in neovascular age-related macular Degeneration: Results with Ranibizumab from the TREND Study. Ophthalmology. https://doi.org/10.1016/j.ophtha.2017.07.014

18.

Berg K, Hadzalic E, Gjertsen I, et al (2016) Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the Lucentis compared to Avastin study treat-and-extend Protocol: Two-Year Results. Ophthalmology. https://doi.org/10.1016/j.ophtha.2015.09.018

19.

Parravano M, Borrelli E, Costanzo E et al (2020) Protect healthcare workers and patients from COVID-19: the experience of two tertiary ophthalmology care referral centers in Italy. Ophthalmol Therapy. https://doi.org/10.1007/s40123-020-00251-z

20.

Borrelli E, Sacconi R, Querques L et al (2020) Taking the right measures to control COVID-19 in ophthalmology: the experience of a tertiary eye care referral center in Italy. Eye. https://doi.org/10.1038/s41433-020-0880-6

21.

Corradetti G, Corvi F, Nguyen TV, Sadda SR (2020) Management of neovascular age-related macular degeneration during the COVID-19 pandemia. Ophthalmol Retin. https://doi.org/10.1016/j.oret.2020.05.015

22.

Shmueli O, Chowers I, Levy J (2020) Current safety preferences for intravitreal injection during COVID-19 pandemic. Eye (Lond). https://doi.org/10.1038/s41433-020-0925-x

23.

Iovino C, Caporossi T, Peiretti E (2020) Vitreoretinal surgery tip and tricks in the era of COVID-19. Graefes Arch Clin Exp Ophthalmol 1–2 . https://doi.org/10.1007/s00417-020-04800-x

24.

Borrelli E, Grosso D, Vella G et al (2020) Impact of COVID-19 on outpatient visits and intravitreal treatments in a referral retina unit: let’s be ready for a plausible “rebound effect”. Graefes Arch Clin Exp Ophthalmol. https://doi.org/10.1007/s00417-020-04858-7

25.

Holz FG, Tadayoni R, Beatty S et al (2016) Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2015-308166

26.

Holladay JT (1997) Proper method for calculating average visual acuity. J Refract Surg 13:388–391PubMed

27.

Huang Y, Gangaputra S, Lee KE et al (2012) Signal quality assessment of retinal optical coherence tomography images. Invest Ophthalmol Vis Sci 53:2133–2141. https://doi.org/10.1167/iovs.11-8755CrossRefPubMedPubMedCentral

28.

Sadda SR, Guymer R, Holz FGFG et al (2018) Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. https://doi.org/10.1016/j.ophtha.2017.09.028

29.

Lee SY, Stetson PF, Ruiz-Garcia H, et al (2012) Automated characterization of pigment epithelial detachment by optical coherence tomography Investig Ophthalmol Vis Sci 53. https://doi.org/10.1167/iovs.11-8188

30.

Jung JJ, Chen CY, Mrejen S et al (2014) The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration. Am J Ophthalmol 158:769–779.e2. https://doi.org/10.1016/j.ajo.2014.07.006CrossRefPubMed

31.

Dansingani KK, Tan ACS, Gilani F et al (2016) Subretinal hyperreflective material imaged with optical coherence tomography angiography. Am J Ophthalmol 169:235–248. https://doi.org/10.1016/j.ajo.2016.06.031CrossRefPubMed

32.

Nassisi M, Lei J, Abdelfattah NS et al (2019) OCT risk factors for development of late age-related macular degeneration in the fellow eyes of patients enrolled in the HARBOR study. Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.05.016

33.

Holz FG, Tadayoni R, Beatty S et al (2015) Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. https://doi.org/10.1136/bjophthalmol-2014-305327

34.

Guymer RH, Markey CM, McAllister IL et al (2019) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results. Ophthalmology. https://doi.org/10.1016/j.ophtha.2018.11.025

Titel: Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic
verfasst von: Enrico Borrelli
Domenico Grosso
Giovanna Vella
Riccardo Sacconi
Marco Battista
Lea Querques
Ilaria Zucchiatti
Francesco Prascina
Francesco Bandello
Giuseppe Querques
Publikationsdatum: 03.10.2020
Verlag: Springer Berlin Heidelberg
Schlagwort: COVID-19
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 12/2020
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-020-04955-7

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Short-term outcomes of patients with neovascular exudative AMD: the effect of COVID-19 pandemic

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

External limiting membrane angle as a composite predictive index for post-operative ELM closure in full thickness macular holes

Extraocular silicone oil migration to orbit and retrolaminar region: case report and systematic review

The novel mutation P36R in LRP5L contributes to congenital membranous cataract via inhibition of laminin γ1 and c-MAF

Isolated choroidal melanocytosis: clinical update on 37 cases

Slit-lamp evaluation during SARS-CoV-2 pandemic: safety first!

Sex judgment using color fundus parameters in elementary school students

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde